Skip to content
Calculator
Guide

Antimicrobial peptides: the antibiotic pipeline's long shot

Last updated: October 28, 2026 · 9 min read · By the Grey Peptides Editorial Board

Petri dishes in a laboratory
Photo by Edward Jenner on Pexels
Grey Peptides
Grey Peptides Editorial Board
Every status on this page carries the date it was checked. How we work
Key takeaways
  • Two peptide classes became important antibiotics: daptomycin and the polymyxins. Both are drugs of last resort.
  • Colistin caused kidney injury in about a third of patients across randomised trials.
  • Several antimicrobial peptides failed large phase 3 trials: iseganan twice, pexiganan partly, omiganan in catheter infections, and murepavadin's trials were stopped.
  • The laboratory activity is real; translating it into a benefit a trial can measure is where they fail.

Why they looked like the answer

Antimicrobial peptides such as the defensins and the human cathelicidin LL-37 are part of the body's own defences, with broad activity against bacteria, viruses and fungi, including bacteria resistant to conventional antibiotics 1 2. The two peptide classes that became antibiotics kill by disrupting bacterial membranes 3.

Translating that into a medicine turned out to be a different problem. Human trials of antimicrobial peptides are a long list of near misses, and the few that became drugs are used when little else works.

Peptide antibioticWhere it got to
DaptomycinApproved 2003 (Cubicin); a mainstay for serious Gram-positive infections, not indicated for pneumonia, and losing ground to resistance 4 5 6
Colistin and polymyxin BColistimethate approved 1970 (Coly-Mycin M); drugs of last resort for carbapenem-resistant Gram-negatives, with kidney toxicity in about a third of patients in randomised trials 4 3 7
BacitracinAn over-the-counter first-aid antibiotic ointment ingredient 8
NisinNot a drug; a food ingredient affirmed as generally recognised as safe 9
IsegananTwo phase 3 trials (545 and 502 patients) in oral mucositis; no benefit over placebo 10 11
PexigananTwo phase 3 trials in 835 patients with infected diabetic foot ulcers; one failed to show equivalence; no FDA application on record 12 4
OmigananCatheter-site infection phase 3 missed its primary endpoint; no FDA application on record 13 4
LL-37Phase 2b in 148 leg-ulcer patients found no significant benefit on the full population 14
Murepavadin (peptidomimetic)Both intravenous phase 3 trials terminated after a safety data review 15

The two that worked

Daptomycin is a cyclic lipodepsipeptide first approved in the United States on September 12, 2003, as Cubicin 4; its current label covers complicated skin and skin-structure infections and Staphylococcus aureus bloodstream infections, and states that it is not indicated for pneumonia 5. Other makers' daptomycin has been approved since 2013 4. A review describes it as a mainstay for serious Gram-positive infections, including methicillin-resistant S. aureus and vancomycin-resistant enterococci, and one of the last-resort antibiotics for life-threatening infections that do not respond to first-line treatment, while noting that resistance is eroding its efficacy (review) 6. In its pivotal trial, 246 patients with S. aureus bloodstream infection were randomised; success 42 days after the end of therapy was 44.2% with daptomycin against 41.7% with standard therapy, meeting the trial's non-inferiority criteria, and clinically significant kidney dysfunction was less common on daptomycin (11.0% against 26.3%), though microbiological failure was more common (19 patients against 11) and isolates with reduced susceptibility to daptomycin emerged in six of those 19 (randomised trial) 16.

The polymyxins, colistin and polymyxin B, are older; colistimethate was approved in the US in 1970 4. A 2022 review sets out how the two classes differ despite similar structures: the polymyxins target lipopolysaccharide in Gram-negative membranes and are often used against carbapenem-resistant species, while daptomycin requires membrane phosphatidylglycerol and is used only against drug-resistant Gram-positives (review) 3. Both disrupt membranes, are potently bactericidal, and share similarities in resistance mechanisms 3.

What last resort costs

The polymyxins are used despite their toxicity, not because they lack it. A meta-analysis of five randomised trials with 377 patients, most receiving colistin for pneumonia in intensive care against beta-lactam-based regimens, found kidney toxicity in 36.2% of those given colistin, with a relative risk of 2.40 and a number needed to harm of 5; its authors concluded that colistin should be regarded as a last-line agent and safer alternatives considered when possible (meta-analysis) 7.

Daptomycin carries a different limitation that is instructive about peptides generally. It failed to meet statistical non-inferiority criteria in a trial in severe community-acquired pneumonia. Scientists at Cubist Pharmaceuticals, its developer, then showed that daptomycin interacts with pulmonary surfactant in the laboratory, which inhibits its antibacterial activity; in animal models it worked in S. aureus pneumonia spread through the blood and in inhalation anthrax but not against pneumococcus in simple bronchial-alveolar pneumonia (laboratory and animal study) 17. Its label now excludes pneumonia 5.

The failures, and what they have in common

The clearest run of failures is in oral mucositis, the mouth ulceration caused by cancer treatment, where the hypothesis was that oral microbes contribute. Iseganan, an analogue of the pig peptide protegrin-1, was tested twice. In 545 patients receiving radiotherapy for head and neck cancer, 9% of patients in both the iseganan and placebo groups avoided ulcerative mucositis (p = 0.998), while only 2% did on standard care alone (randomised trial) 10. In 502 patients receiving stomatotoxic chemotherapy, 43% on iseganan and 37% on placebo avoided moderate or worse stomatitis (p = 0.182), with no significant difference in severity, ulceration, mouth pain, swallowing or painkiller use (randomised trial) 11. Drugs@FDA lists no application for iseganan 4.

Pexiganan, an analogue of a frog peptide, was tested as a cream in 835 patients with mildly infected diabetic foot ulcers against oral ofloxacin: one of the two phase 3 trials failed to show equivalence, while the other and the combined data showed equivalent clinical improvement, around 85% to 90%, and similar microbiological eradication, 42% to 47% (randomised trials) 12. Drugs@FDA lists no application for it 4. Omiganan was tested against povidone-iodine in a phase 3 trial of 1,859 patients with central venous catheters: its primary endpoint, local catheter-site infection, was not significantly different (50 against 70 events, p = 0.082), though microbiologically confirmed infections and catheter colonisation were lower 13. Its later dermatology trials are covered in our acne and rosacea guide.

Even the body's own peptide has struggled. In HEAL LL-37, a phase 2b trial in 148 patients with hard-to-heal venous leg ulcers sponsored and co-written by Promore Pharma, LL-37 at two concentrations alongside compression showed no significant improvement in healing against placebo on the full study population, though a post hoc analysis found differences on several related healing measures in patients with large wounds (randomised trial) 14.

The mucositis programme is the most instructive of the set. Iseganan was delivered straight to the tissue in question and still changed nothing against placebo, and the radiotherapy trial's authors concluded that antimicrobial intervention may not meaningfully affect how radiation mucositis develops; the rinse vehicle or the extra oral hygiene appeared to help on its own 10.

A pattern runs through these. The peptides were active against the organisms in the laboratory. What they failed to do was change the clinical outcome the trial measured, whether because the outcome depended on more than the microbes 10 or because the peptide was inhibited in the environment it was placed in 17.

Why translation is so hard

Reviews of the defensins and of LL-37 name the same obstacles: low stability against the body's protein-cutting enzymes, short circulation time, toxicity to human cells, and the cost of manufacturing peptides at scale; delivery to the site of infection is a further problem 1 2. Our manufacturing guide covers how peptides are made.

Resistance has also proved possible. The 2022 review notes that the polymyxins and lipopeptides share similarities in resistance mechanisms despite their distinct targets 3, the daptomycin review records resistance eroding its clinical efficacy 6, and reduced susceptibility emerged during treatment in daptomycin's pivotal trial 16.

What is still being tried

The newer attempts mostly change the molecule rather than the idea. Murepavadin is a peptidomimetic, a designed molecule based on a peptide, with a non-lytic mechanism that targets an outer-membrane protein of Pseudomonas aeruginosa rather than disrupting membranes 18; a 2026 laboratory study names the target as the LptD protein 19. A 2018 review co-written by an employee of its developer, Polyphor, described it as a new antibiotic class in phase 3 development for hospital-acquired and ventilator-associated pneumonia caused by P. aeruginosa (review) 18. Both Polyphor phase 3 trials of intravenous murepavadin are listed on ClinicalTrials.gov as terminated, with 'safety data review' as the reason 15. It is still studied in the laboratory, including against biofilms and in combination with conventional antibiotics (laboratory study, 50 clinical isolates) 19.

Other approaches modify the natural peptides themselves: truncated and retro (reversed-sequence) analogues of LL-37 with less toxicity and more resistance to protease breakdown, and nanoscale delivery systems that target the peptide and prolong its half-life 2 1.

Where they do earn their place

Two uses show what works. Bacitracin, a peptide antibiotic, is listed among the over-the-counter first-aid antibiotic active ingredients, as an ointment of 500 units per gram 8. Nisin is not a drug at all: FDA's food regulations affirm a nisin preparation, a group of related peptides with antibiotic activity, as generally recognised as safe for specified food uses 9. Both are applied locally, to the skin or in food, rather than injected. The same kind of molecule clears a different bar depending on its purpose: a food ingredient and a first-aid ointment are each regulated for that use alone 8 9.

What this means for peptides sold as research chemicals

None of this makes an antimicrobial peptide bought as a research chemical into a treatment. LL-37 is on FDA's safety-risks page among substances whose compounding nominations were withdrawn; FDA notes nonclinical findings suggesting harm to male reproduction and says it lacks sufficient safety information to know whether the drug would cause harm 20. Our LL-37 guide sets out what its trials found. Choosing a peptide because it kills bacteria in a laboratory is the inference the trials above tested and mostly refuted.

The bottom line

Antimicrobial peptides produced two classes of important drugs, both reserved for infections that have defeated everything else, and both with real costs: kidney injury for the polymyxins 7, inactivation by surfactant and creeping resistance for daptomycin 17 6. The others cited here that reached a large trial, iseganan twice, pexiganan partly, omiganan, LL-37, failed to show the benefit their laboratory activity promised, and murepavadin's phase 3 trials were stopped 10 11 12 13 14 15.

Frequently asked questions

Are antimicrobial peptides used as antibiotics?

Yes, two classes: daptomycin and the polymyxins (colistin and polymyxin B). Both are reserved for infections resistant to other treatments.

Why do antimicrobial peptides fail in trials?

Reviews point to breakdown by protein-cutting enzymes, short circulation, toxicity to human cells and manufacturing cost; and in trials, killing microbes often did not change the outcome measured.

How toxic is colistin?

In a meta-analysis of five randomised trials, kidney toxicity occurred in 36.2% of colistin patients, with a relative risk of 2.40 against beta-lactam-based regimens.

Why did daptomycin fail in pneumonia?

Pulmonary surfactant inhibits its antibacterial activity, shown in laboratory work by its developer's scientists after the trial missed its non-inferiority criteria. Its label says it is not indicated for pneumonia.

Is LL-37 a treatment for wounds?

No. In a 148-patient trial in hard-to-heal venous leg ulcers, it showed no significant improvement over placebo on the full study population.

Sources

  1. Gao, X., et al. (2021). Defensins: The natural peptide antibiotic. Adv Drug Deliv Rev, 179, 114008. PMID: 34673132
  2. Voronko, O. E., et al. (2025). Antimicrobial Peptides of the Cathelicidin Family: Focus on LL-37 and Its Modifications. Int J Mol Sci, 26(16). PMID: 40869425
  3. Ledger, E. V. K., et al. (2022). Polymyxin and lipopeptide antibiotics: membrane-targeting drugs of last resort. Microbiology (Reading), 168(2). PMID: 35118938
  4. FDA. Drugs@FDA via openFDA: daptomycin, NDA 021572 (Cubicin), original approval September 12, 2003, with other makers' applications from 2013; colistimethate, NDA 050108 (Coly-Mycin M), June 4, 1970; no application for pexiganan, omiganan, iseganan or murepavadin. Searched October 28, 2026.
  5. Merck Sharp & Dohme. CUBICIN RF (daptomycin) prescribing information, section 1 (indications; limitations of use: not indicated for pneumonia). DailyMed set 0b1a8885, version 22, effective March 17, 2025; read October 28, 2026. DailyMed
  6. Taylor, S. D., et al. (2025). Daptomycin: Mechanism of action, mechanisms of resistance, synthesis and structure-activity relationships. Prog Mol Biol Transl Sci, 212, 163-234. PMID: 40122645
  7. Eljaaly, K., et al. (2021). Colistin Nephrotoxicity: Meta-Analysis of Randomized Controlled Trials. Open Forum Infect Dis, 8(2), ofab026. PMID: 33623807
  8. 21 CFR 333.110, First aid antibiotic active ingredients: bacitracin ointment and bacitracin zinc ointment among the listed ingredients. eCFR, read October 28, 2026. eCFR
  9. 21 CFR 184.1538, Nisin preparation: a group of related peptides with antibiotic activity, affirmed as generally recognized as safe for specified food uses. eCFR, read October 28, 2026. eCFR
  10. Trotti, A., et al. (2004). A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. Int J Radiat Oncol Biol Phys, 58(3), 674-81. PMID: 14967419
  11. Giles, F. J., et al. (2004). A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy. Leuk Res, 28(6), 559-65. PMID: 15120931
  12. Lipsky, B. A., et al. (2008). Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream. Clin Infect Dis, 47(12), 1537-45. PMID: 18990064
  13. ClinicalTrials.gov NCT00231153 (Cadence Pharmaceuticals): phase 3, randomised, evaluation-committee-blinded trial of omiganan 1% gel against povidone-iodine in 1,859 patients with central venous catheters, completed July 2008; posted results: local catheter-site infection 50 against 70 events, p = 0.082; microbiologically confirmed infection 31 against 62 (p = 0.002); colonisation 369 against 478 (p < 0.001). Read October 28, 2026. ClinicalTrials.gov
  14. Mahlapuu, M., et al. (2021). Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: A multicentric prospective randomized placebo-controlled clinical trial. Wound Repair Regen, 29(6), 938-950. PMID: 34687253
  15. ClinicalTrials.gov NCT03409679 and NCT03582007 (Polyphor Ltd.): phase 3 trials of intravenous murepavadin (POL7080) in ventilator-associated and nosocomial pneumonia due to Pseudomonas aeruginosa, both terminated; reason given: 'Safety data review'. Read October 28, 2026. ClinicalTrials.gov
  16. Fowler VG, J. r., et al. (2006). Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med, 355(7), 653-65. PMID: 16914701
  17. Silverman, J. A., et al. (2005). Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis, 191(12), 2149-52. PMID: 15898002
  18. Martin-Loeches, I., et al. (2018). Murepavadin: a new antibiotic class in the pipeline. Expert Rev Anti Infect Ther, 16(4), 259-268. PMID: 29451043
  19. Yılmaz, U., et al. (2026). Murepavadin is a novel peptide antibiotic that exhibits potent antibiofilm activity and enhances the efficacy of conventional antibiotics against Pseudomonas aeruginosa. Biofouling, 42(7), 771-781. PMID: 42459059
  20. FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of April 22, 2026): cathelicidin LL-37, in the table of substances previously in Category 2 whose nominations were withdrawn. Read October 28, 2026. FDA

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.

All articles

New guides and rule changes, by email

One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.

We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead